Articles related to ACUTE CORONARY SYNDROME (ACS)
Milvexian Fast Tracked for Ischemic Stroke, Acute Coronary Syndrome, and Atrial Fibrillation
Accelerate your understanding of thrombotic disease treatment developments; delve into the Fast Track designation of milvexian, a promising oral factor XIa inhibitor.
Cardiology June 28th 2023
Questioning Aspirin’s Role After Percutaneous Coronary Intervention and Acute Coronary Syndrome
Most current guidelines recommend at least 12 months of dual anti-platelet therapy for ACS and post PCI. But is that the best approach in an aging population with inherent higher bleeding risk? Some are advocating very early cessation of aspirin as well as scaling down the P2Y12 inhibitor in the first few months post event.
Cardiology January 5th 2022
ACS Risk Biomarkers Significantly Increase After mRNA COVID-19 Vaccine
This study involved 566 men and women between the ages of 28 and 97 years, who were patients in a preventive cardiology practice. The PULS Cardiac Test measures multiple protein biomarkers, including hepatocyte growth factor, soluble Fas, and IL-16, and uses the results to calculate a five-year risk score for new ACS. All factors more than doubled their prior above the norm level. The 5-year ACS PULS risk score more than doubled as a result.
Cardiology November 30th 2021